Keyphrases
Metastatic Melanoma
100%
Nivolumab
100%
Aldesleukin
100%
Treatment-related
50%
Polyfunctional
50%
Median Progression-free Survival
50%
Objective Response Rate
50%
Target Lesion
50%
Immune-related Adverse Events
50%
Online Treatment
50%
Radiologic
25%
Low Dose Rate
25%
Melanoma
25%
Interleukin-2
25%
Eosinophils
25%
Overall Survival
25%
Effector Function
25%
Blood Biomarkers
25%
Antitumor Activity
25%
Treatment Response
25%
Complete Response Rate
25%
Durable Response
25%
Median Overall Survival
25%
Progression-free Survival
25%
Stage III-IV
25%
CD81
25%
Overall Survival Rate
25%
% Response
25%
Strength Difference
25%
Change in Size
25%
Previously Untreated Patients
25%
Safety Response
25%
Complete Clearance
25%
CD122
25%
CD41 T Cells
25%
Blinded Independent Central Review
25%
CD81 T Cells
25%
Medicine and Dentistry
Metastatic Melanoma
100%
Nivolumab
100%
Biological Marker
75%
Overall Survival
75%
Progression Free Survival
75%
Adverse Event
50%
Target Lesion
50%
Eosinophil
25%
Nodular Melanoma
25%
Interleukin 2
25%
Cytokine
25%
T Cell
25%
Survival Rate
25%
Arm
25%
Treatment Response
25%
Antineoplastic Activity
25%
Pharmacology, Toxicology and Pharmaceutical Science
Metastatic Melanoma
100%
Nivolumab
100%
Biological Marker
75%
Overall Survival
75%
Progression Free Survival
75%
Adverse Event
50%
Melanoma
25%
Cytokine
25%
Interleukin 2
25%
Survival Rate
25%
Antitumor Activity
25%
Immunology and Microbiology
Nivolumab
100%
Overall Survival
75%
Progression Free Survival
75%
CD81
50%
T Cell
25%
Cytokine
25%
Interleukin 2
25%
Eosinophil Granulocyte
25%
Survival Rate
25%
Agonist
25%
Arm
25%
Antineoplastic Activity
25%